EIKN Eikon Therapeutics, Inc.

Price Chart

Executive Summary

Eikon Therapeutics presented updated Phase 2 data for EIK1001 (TLR7/8 agonist) in first-line NSCLC at ASCO 2026, showing a 63.1% ORR and 90.8% DCR across 65 evaluable patients, with median DOR >11 months in the non-squamous cohort. The company also reported initial Phase 1/2 data for EIK1003 (PARP1-selective inhibitor) showing 14.3% ORR as monotherapy and 24.5% ORR in combination with paclitaxel. These are early-stage clinical data readouts with no financial figures or guidance provided.

Actionable Insight

Key Facts

• EIK1001 Phase 2 TeLuRide-005 trial in first-line stage 4 NSCLC: 63.1% ORR and 90.8% DCR across 65 efficacy-evaluable patients (non-squamous + squamous)
• Non-squamous cohort (n=36): 55.6% ORR, 83.3% DCR, median follow-up 13.6 months, median DOR >11 months
• Squamous cohort (n=29): 72.4% ORR, 100% DCR, median follow-up 8.8 months (data still maturing)
• EIK1003 Phase 1/2 monotherapy (Cohort 1A, n=49 evaluable): 14.3% ORR overall, 26.7% in PARP-naïve patients, median DOR 7.8 months
• EIK1003 + paclitaxel (Cohort 1C, n=53 evaluable): 24.5% ORR, 29.6% in platinum-resistant ovarian cancer, 19.2% in breast cancer
• No financial data, revenue, earnings, or guidance was provided in this filing

Financial Impact

No financial figures reported; clinical data readouts only

Risk Factors

• Pre-revenue biotech with no approved products and significant cash burn
• EIK1001 and EIK1003 are still in Phase 2 and Phase 1/2 respectively; regulatory and clinical failure risk remains high
• No financial guidance or cash runway disclosed in this filing

Market Snapshot

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

US Market Status